Depression
Our goal at Pathways Neuro Pharma, Inc. is to ease the suffering of millions of people affected by depression. We are focusing on new discoveries of the physiological underpinnings of this condition, emphasizing that it is a disease with a biological basis, not a character flaw or moral failing.
The Pathways proprietary combination of gene therapy and pharmaceutical drug approaches targets key neurological pathways involved in mood regulation. Our approach seeks to rebalance these pathways, allowing those affected by chronic depression to lead more normal lives.
We are working at the intersection of neurological pathways that coordinate mood regulation through the brain's production of serotonin and dopamine. Recent discoveries have uncovered important roles for serotonin receptors (5-HT) and dopamine receptors (DRD1). Our focus includes increasing the expression of these receptors and enhancing their function to improve mood regulation.
Our research involves the use of selective serotonin reuptake inhibitors (SSRIs), which work by increasing the levels of serotonin in the brain by inhibiting its reabsorption into neurons. This increased availability of serotonin enhances neurotransmission and improves mood in individuals with depression. Additionally, we are investigating the role of DRD1 in regulating dopamine pathways, as dopamine is crucial for motivation and pleasure.
We are collaborating with academic partners and qualified Clinical Research Organizations to develop a DNA therapy that increases the expression of 5-HT and DRD1 receptors. We have successfully manufactured DNA constructs which, when administered in an animal model, have increased the expression of these receptors in brain tissue. In already completed animal trials, the activation of these pathways resulted in improved mood and behavior.
Of particular interest, our treatments have shown promise in reducing symptoms of anhedonia and fatigue, which are common in depression. By targeting serotonin uptake and enhancing dopamine signaling, we believe our approach can significantly reduce the severity of depression and improve the quality of life for those affected.
